Navigation Links
Cancer drug may also work for scleroderma
Date:9/22/2011

CHICAGO --- A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

The drug, with the generic name bortezomib, stopped the production of fibrotic proteins in human cells and the development of fibrous scarring in a mouse model of fibrotic disease, according to a new Northwestern Medicine study published in the journal Thorax.

"This drug appears to put the brakes on abnormal development of scar tissue in the lungs and skin and may also work in other organs," said lead author Manu Jain, M.D., associate professor of medicine and of pediatrics at Northwestern University Feinberg School of Medicine and a physician at Northwestern Memorial Hospital and Children's Memorial Hospital. "These diseases have a high fatality rate, and there is no truly effective treatment for them right now."

Scleroderma is an autoimmune disease that causes progressive thickening and tightening of the skin and can lead to serious internal organ damage and, in some cases, death. Scleroderma affects an estimated 300,000 people in the United States, most frequently young to middle-aged women.

Idiopathic pulmonary fibrosis is a scarring or thickening of the lungs without any known cause that makes it increasingly difficult to breathe. It may affect up to 200,000 people in the U.S. between 50 and 70 years old.

Jain said the drug appears to inhibit a protein called transforming growth factor beta, which is essential for the growth of the scar tissue. Patients with fibrosis have increased levels and activity of the growth factor. Bortezomib is currently used to treat multiple myeloma and lymphoma.

In the study, when researchers gave bortezomib to mice, it prevented the development of a fibrotic-like disease. "The mice that normally get this disease didn't get it," Jain said.

Researchers also took fibroblast cells from scleroderma and pulmonary fibrosis patients and incubated those cells with the drug. Fibroblast cells are believed to be important in the development of scarring in humans. The drug prevented the expression of proteins that are necessary for scarring.


'/>"/>

Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests
2. Virus kills breast cancer cells in laboratory
3. Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky
4. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
5. New Test Predicts Risk for Impotence After Prostate Cancer Therapy
6. Genes May Explain Blacks Bleaker Prostate Cancer Stats
7. The War on Cancer Continues
8. John Theurer Cancer Center among first clinical trial sites to join landmark MMRF study
9. MRI Can Spot Breast Cancer in High-Risk Women: Study
10. Higher Risk of Second Breast Cancer Seen in Black Women
11. 10 ways to make better decisions about cancer care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... 29, 2017 , ... Saturday, April 29, marks World Veterinary ... have on animal health and welfare as well as on public health. The ... a theme each year and this year have selected “Antimicrobial Resistance—From Awareness to ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... It's not ... are a number of illnesses that are unclear as to whether or not they ... heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into the ...
(Date:4/28/2017)... ... ... much more than energy – it also has mental and physical benefits. According to the ... which can increase the risk of having a car accident. , This week is ... help you sleep better and feel better:, , Turn off all ...
(Date:4/28/2017)... VA (PRWEB) , ... April 28, 2017 , ... The ... volunteer board members and officers for 2017-2018. The annual board election process has been ... on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, ...
(Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology: